Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Anastasis Biotec Limited is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity involves 1 distinct examiner and 1 distinct art unit. LI N KOMATSU is the busiest examiner, holding the 1 pending office action. The portfolio's current USPTO activity is limited to a single examiner and a single art unit, which suggests a very focused entry into the biotechnology patent landscape. This concentration means that the prosecution strategy does not need to account for diverse examiner behaviors or different art unit policies.
Practitioners should focus on the specific technical requirements of LI N KOMATSU within the Biotechnology & Pharmaceuticals sector to resolve the 1 pending office action efficiently. Because there is only 1 distinct examiner involved, the applicant can tailor all arguments to a single set of expectations. This streamlined approach reduces administrative overhead and allows for a more direct path toward potential allowance. The focus on a single art unit also ensures that the applicant only needs to comply with one set of internal guidelines, which is beneficial for maintaining a consistent prosecution record for this specific technology.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257827 | IMPROVED CELL-PENETRATING PEPTIDES AND FUSION PROTEINS | KOMATSU, LI N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257827 | IMPROVED CELL-PENETRATING PEPTIDES AND FUSION PROTEINS | KOMATSU, LI N | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18257827 | IMPROVED CELL-PENETRATING PEPTIDES AND FUSION PROTEINS | KOMATSU, LI N | 1658 | §102§103§112Other | Non-Final OA | — | Pending | Jun 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAnastasis Biotec Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Li N Komatsu has the most, with 1 of Anastasis Biotec Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
